 - Subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of PS433540, including cardiovascular includes subjects who are known to have coronary artery disease, renal including the absence of one kidney, pulmonary, hepatic, gastrointestinal including clinically significant malabsorption, endocrinemetabolic, hematologic, neurologic and psychiatric diseases. 